Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lunasin-enriched soy extract is a dietary supplement derived from soybeans and specifically enriched for the bioactive peptide lunasin. Lunasin is a 43–44 amino acid peptide with an intramolecular disulfide bond, naturally present in soy and some other grains. The extract contains significantly higher concentrations of lunasin compared to standard soy protein isolates[4][9]. Mechanistically, lunasin exhibits antioxidant, anti-inflammatory, hypocholesterolemic (cholesterol-lowering), and anticancer properties. It acts epigenetically by binding to histone H3 and inhibiting its acetylation by PCAF histone acetylase enzyme; this downregulates HMG-CoA reductase expression (the rate-limiting enzyme in cholesterol biosynthesis) and upregulates LDL receptor expression in liver cells[4]. Lunasin also reduces reactive oxygen species (ROS) production and pro-inflammatory cytokines such as interleukin-1β and interleukin-8[1][5][9]. In cancer models, it inhibits cell proliferation via disruption of mitotic spindle formation and modulates integrin-mediated cell adhesion pathways[7][8]. The product is typically administered orally as capsules or powders but can be formulated into various oral dosage forms[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lunasin-enriched soy extract.